A World Without Infectious Disease

A new era

We are developing a broad portfolio of product candidates that are designed to combat serious, global infectious diseases in entirely new ways, creating medicines that will have a meaningful impact on people around the world.

Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.

HBV

Platform

VIR-2218

siRNA
    
Hepatitis B virus (HBV) treatment

VIR-2218, an HBV-targeting siRNA, is designed to inhibit the production of all HBV proteins, including hepatitis B virus surface antigen (HBsAg), which in turn is hypothesized to remove the inhibition of T cell activity directed against HBV. We believe that achieving a functional cure for many HBV patients may be enabled by using VIR-2218 in combination with other agents. (Functional cure is defined as life-long control of the virus after a finite duration of therapy.)

VIR-3434

Antibody
    
Hepatitis B virus (HBV) treatment

VIR-3434, an HBV-neutralizing monoclonal antibody, is designed to block entry of all 10 genotypes of HBV into liver cells and reduce the level of virions and sub-viral particles in the blood. VIR-3434 has been engineered to have an extended half-life and to potentially function as a T cell vaccine against HBV in infected patients. We believe that achieving a functional cure for many HBV patients may be enabled by using VIR-3434 in combination with other agents. (Functional cure is defined as life-long control of the virus after a finite duration of therapy.)

Influenza A

Platform

VIR-2482

Antibody
    
Influenza A prophylaxis

VIR-2482 is designed as a universal prophylactic for influenza A to overcome the limitations of flu vaccines and lead to meaningfully higher levels of protection because it has broad strain coverage. We also believe that it provides passive immunity rather than relying on a person’s own immune system to create protective influenza virus antibodies. VIR-2482 has been half-life engineered so that a single dose has the potential to last the entire flu season, which is typically five to six months long.

HIV

Platform

VIR-1111

T Cell
    
Human immunodeficiency virus (HIV) prophylaxis

VIR-1111, an HIV T cell vaccine based on human cytomegalovirus (HCMV), a commonly occurring virus in humans, is designed to elicit T cells that recognize HIV epitopes that are different from those recognized by prior HIV vaccines and to stimulate a different and specific type of T cell immune response to HIV known as an HLA-E restricted immune response. VIR-1111 is designed to establish proof of concept in a Phase 1 clinical trial to determine whether the unique immune response observed in pre-clinical trials can be replicated in humans. Ultimately, any candidates we advance as a potential HIV vaccine will require modifications to VIR-1111 before further clinical development.

TB

Platform

VIR-2020

T Cell
    
Tuberculosis (TB) prophylaxis

VIR-2020, a TB T cell vaccine based on human cytomegalovirus (HCMV), a commonly occurring virus in humans, is designed to stimulate T cells that reside in the lung and to recognize parts of TB epitopes that are different from those recognized by prior TB vaccines.

Our Focus

Chronic and acute infections impact hundreds of millions of people every year.

We are taking aim at some of the world’s largest and most serious infectious diseases, infections that have long been evasive, challenging, or insufficiently addressed by current approaches. Our vision is that one day, diseases like hepatitis B, influenza A, HIV, and tuberculosis become a thing of the past.

Collaborators to advance our technologies and enable global access

We are collaborating with leading companies and organizations to advance our innovative technologies and to enable global access to our future medicines, including:

alnylam logo

BriiBio logo

bill and melinda gates logo

Institute for Research in Biomedicine logo

OHSU logo